Sign in Subscribe
3 min read

Get the Straight DOPE - Issue #2

Get the Straight DOPE - Issue #2

Welcome to the second edition of DOPE, the Finnrick.com newsletter, where we're separating peptide fact from fiction with the precision of a well-calibrated HPLC machine. Like your favorite reality show, our testing reveals who's bringing pharmaceutical-grade quality and who's serving pharmaceutical-grade disappointment.

🔬
Lab Update: We've analyzed 198 new peptide samples last month, covering 7 new vendors. Our focus remains on GLP-1 agonists and recovery peptides, but now also cover Bremelanotide. And as always, we test multiple samples per vendor, product, and batch, across several commercial labs, to establish reliability patterns.

Vendor Spotlight:
The Good, The Bad, The Inconsistent

Sourcing samples from additional vendors hasn't increased our belief in humanity.

👑 Royal Peptides

A solid performer in this new crop. Their Retatrutide and Semaglutide both earned solid B ratings with consistent test scores. They'd do even better with batch IDs on the vials so the public can track quality over time.

👎 Peptide Gurus

Affordable new entrant disappoints with 4 products already rated E, including Retatrutide that might actually be Tesamorelin – yeah, not ideal, perhaps the economics are too good to be true. That said, their Semaglutide achieved a B.

🥊 Suaway Lab Research

Talk about enthusiasm! Suaway's Retatrutide contained a whopping 42% more peptide than advertised. While their Ipamorelin earned an A rating with near-perfect 99.9% purity, their Tirzepatide went full overachiever with 83% more product than labeled. Generous? Yes. Concerning for precise dosing? Also yes.

The Jekyll & Hyde Vendors

Vendors with the most dramatic quality differences across their product lines

Vendor Best Product Rating Worst Product Rating
Peptide Sciences Semaglutide A Retatrutide E
Loti Labs Retatrutide A CJC-1295 E
Paramount Peptides Ipamorelin A BPC-157 D
NextechLabs Semaglutide A BPC-157 D

Sovereign Health News

  • Oral GLP-1 Breakthrough: Eli Lilly's orforglipron data is about to drop, potentially showing 13-15% weight reduction comparable to injectable semaglutide, but in pill form. This could revolutionize metabolic treatment accessibility.
  • Novo Nordisk's $2B Chinese Gambit. Novo just dropped $2 billion to license UBT251, a triple-hormone obesity drug candidate from China's United Labs. This next-gen compound targets three hormones compared to Wegovy's single-GLP-1 approach, potentially revolutionizing metabolic intervention.
  • Stanford's "Natural Ozempic": Researchers identified a naturally occurring 12-amino acid peptide called BRP that mimics Ozempic's weight loss effects without the gut-punching side effects. It reduced food intake by up to 50% in animal studies by targeting brain pathways more precisely.
  • MIT's Dose-Slashing Breakthrough. MIT researchers developed 'in vivo antibody painting' that attaches GLP-1 drugs directly to antibodies inside the body. The result? Sustained weight loss using just ONE-FOURTH the standard drug dose. This could dramatically reduce costs while improving effectiveness.

Have a Peptide You Want Tested?

Our testing program continues to expand. If you have a peptide product you'd like us to analyze, or a vendor you're curious about, we want to hear from you. Mail us a vial for testing (it's free!), or ask Finnrick to source a sample. Your submissions help build a more transparent peptide marketplace for everyone.

Request A Test